articleEurosurveillanceFeb 8, 2024DIAMOND OA

Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

MLMónica López‐LacortCMCintia Muñoz-QuilesAMAinara Mira‐IglesiasFXF. Xavier López‐LabradorBMBeatriz Mengual‐Chuliá

Instituto de Salud Carlos III · Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · +13 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan 2024), where a universal immunisation programme began late September (coverage range: 79-99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.

Citation impact

172
total citations
FWCI
60.19
Percentile
100%
References
15
Citations per year

Authors

28

Topics & keywords

Topics
Keywords
  • Medicine
  • Interim
  • Respiratory tract infections
  • Respiratory system
  • Lower respiratory tract infection
  • Pediatrics
  • Respiratory tract
  • Virus
UN Sustainable Development Goals
  • Peace, Justice and strong institutions
No related works found for this paper.

Funding